Comparing the current results to its competitors, Biora Therapeutics Inc reported Revenue increase in the 4 quarter 2024 by 0 % year on year. The revenue growth was below Biora Therapeutics Inc 's competitors' average revenue growth of 39.57 %, achieved in the same quarter.
Biora Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates within the biotechnology and pharmaceutical industries, which are characterized by rapid technological advancement, intense competition, and a focus on intellectual property and proprietary products. It relies on its proprietary technologies, knowledge, experience, and scientific expertise as competitive advantages. The company faces substantial competition from major pharmaceutical companies, biotechnology firms, academic institutions, government agencies, and both public and private research organizations. Competitors may possess greater financial, technical, and human resources, as well as more experience in developing, obtaining regulatory approval for, and marketing novel treatments and technologies. These factors may provide competitors with advantages in recruiting and retaining qualified personnel, developing similar or superior products, completing clinical development, securing strategic partnerships, and commercializing products. The company anticipates ongoing intense competition from a diverse range of competitors across multiple applications of its technology.
July 18, 2024
: In recent developments, Biora Therapeutics has unveiled supplemental data from its Phase 1 clinical trial of BT-600, presented at a Key Opinion Leader (KOL) event. BT-600, utilizing the innovative NaviCap platform, showcased impressive ability to deliver therapeutic agents topically throughout the entire colon while maintaining low systemic concentrations. This article delves into the pharmacokinetic and tissue distribution findings, and their implications for colonic drug delivery systems. Biora Therapeutics, a pioneering company in the field of targeted drug delivery systems, has recently revealed supplemental data from its Phase 1 clinical trial of BT-600. This trial aimed to evaluate the pharmacokinet...
July 1, 2024
Biora Therapeutics Revolutionizes Colon Delivery of Therapeutics with Positive Clinical Trial Results for BT-600 and the NaviCap PlatformBiora Therapeutics, a leading biotechnology company, recently announced positive clinical trial results for their groundbreaking product, BT-600, along with the successful completion of the Multiple-Ascending Dose (MAD) cohorts. These achievements not only demonstrate the efficiency and safety of BT-600 but also highlight the impressive capabilities of the NaviCap platform in delivering therapeutics directly to the colon.The clinical trial for BT-600 focused on assessing its tolerance and ability to achieve all trial s. The results proved not only its potential as an effect...
June 11, 2024
Biora Therapeutics, a leader in innovative drug delivery solutions, has announced a significant milestone in its mission to revolutionize oral drug delivery systems. The company is set to present preclinical data on their cutting-edge BioJet Systemic Oral Delivery Platform at the Next Gen Peptide Formulation and Delivery Summit on June 19, 2024. Innovation at the ForefrontThe BioJet Systemic Oral Delivery Platform represents a remarkable leap forward in the administration of peptides and other macromolecules, which traditionally face challenges in oral bioavailability. The platform s design allows for the systemic delivery of these therapeutics, potentially transforming how patients with chronic and severe c...
April 30, 2024
Biora Therapeutics, a frontrunner in the biopharmaceutical industry, recently made waves in medical innovation with its announcement on the completion of Multiple-Ascending Dose (MAD) cohorts for the clinical trial of BT-600. The full course of patient dosing has successfully completed, setting expectations for results to become available in late Q2 in 2024.The BT-600 trial is a key landmark in biopharmaceutical research, with ramifications likely to reverberate across the industry and possibly determine future therapeutic directions. Biora’s completion of the MAD cohorts has brought the BT-600 trial one step closer to real-world application, foreshadowing a progressive era in biotechnological advancements...
April 4, 2024
The dawn of a new age in therapeutic management has arrived, as the imminent rise of promising treatments, both in terms of effectiveness and safety, continues to redefine the horizons of our knowledge in medicine. Biora Therapeutics has taken a giant leap in this evolutionary journey of treatment advances, with interim positive clinical trial results of its drug candidate, BT-600. Achieving all pharmacokinetic endpoints, demonstrating the NaviCap platform s operational efficacy, and generating zero safety signals, this recent development positions Biora Therapeutics at a significant place in the global therapeutic landscape.The Clinical Journey of BT-600BT-600, a breakthrough drug candidate under the portfo...
February 26, 2024
In the pharmaceutical industry, the successful completion of clinical trials is a crucial milestone that marks the progress of a potential therapeutic candidate. This article aims to interpret two key announcements made by Biora Therapeutics regarding the Phase 1 clinical study of their drug-device combination, BT-600. We will outline the facts presented in the articles and assess their impact on the company.Fact 1: Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical StudyBiora Therapeutics recently announced the successful completion of the SAD cohorts of their Phase 1 clinical study for BT-600. This indicates that the drug-device combination has bee...
January 2, 2024
Biora Therapeutics, a company known for its innovative solutions in the field of medicine, is marking a new chapter in its research collaboration, demonstrating significant progress for its BioJet Systematic Oral Delivery platform. Rendering a phenomenal performance in a preclinical study, Biora’s BioJet platform has exceeded expectations concerning the conveyance of a collaborator, AstraZeneca s molecule. This development heralds a paradigm shift in healthcare solutions, and it fortifies Biora’s reputation as a distinguished trailblazer in the arena of medical advancements. The BioJet platform optimizes the potentiality of oral delivery mechanisms, making strides towards overcoming the pitfalls of tradi...
Amicus Therapeutics Inc is a biopharmaceutical company that focuses on the development and commercialization of therapies for rare and orphan diseases.
Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.
Ardelyx Inc is a biopharmaceutical company that focuses on the development of novel, minimally-absorbed small molecules to treat gastrointestinal diseases. Their business model revolves around identifying specific needs within the gastrointestinal field and leveraging their research and development capabilities to create innovative therapeutic solutions. By partnering with other pharmaceutical companies and pursuing strategic collaborations, Ardelyx aims to bring its products to market and ultimately improve patient outcomes in the gastrointestinal space.
Biodexa Pharmaceuticals Plc operates as a biopharmaceutical company that focuses on the research, development, and commercialization of innovative medical solutions. Their business model revolves around leveraging scientific expertise to bring new medicines to market and meet the healthcare needs of patients worldwide.
Sources:
Biora Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Biora Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
